Anaplastic Astrocytoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Anaplastic Astrocytoma – Pipeline Review, H2 2016’, provides an overview of the Anaplastic Astrocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma

The report reviews pipeline therapeutics for Anaplastic Astrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Astrocytoma therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Astrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AngioChem Inc.

Astellas Pharma Inc.

Axelar AB

Boehringer Ingelheim GmbH

Burzynski Research Institute, Inc.

Cavion LLC

Celldex Therapeutics, Inc.

Millennium Pharmaceuticals Inc

Novartis AG

Orbus Therapeutics, Inc.

Pfizer Inc.

Tocagen Inc.

TVAX Biomedical, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Anaplastic Astrocytoma Overview 8

Therapeutics Development 9

Pipeline Products for Anaplastic Astrocytoma - Overview 9

Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 10

Anaplastic Astrocytoma - Therapeutics under Development by Companies 11

Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 12

Anaplastic Astrocytoma - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Anaplastic Astrocytoma - Products under Development by Companies 15

Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 16

Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 17

AngioChem Inc. 17

Astellas Pharma Inc. 18

Axelar AB 19

Boehringer Ingelheim GmbH 20

Burzynski Research Institute, Inc. 21

Cavion LLC 22

Celldex Therapeutics, Inc. 23

Millennium Pharmaceuticals Inc 24

Novartis AG 25

Orbus Therapeutics, Inc. 26

Pfizer Inc. 27

Tocagen Inc. 28

TVAX Biomedical, Inc. 29

Anaplastic Astrocytoma - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

afatinib dimaleate - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

alisertib - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Antineoplaston Therapy - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

AXL-1717 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

bendamustine hydrochloride - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

CDX-1401 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Cellular Immunotherapy for Gliomas - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Cellular Immunotherapy for Oncology - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

DNX-2401 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

eflornithine hydrochloride - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

flucytosine + TBio-01 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

flucytosine ER + vocimagene amiretrorepvec - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

irinotecan hydrochloride + TBio-02 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

M-032 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

mibefradil dihydrochloride - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

nilotinib - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

p28 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

paclitaxel trevatide - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

palbociclib - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

TVI-Brain-1 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

Anaplastic Astrocytoma - Dormant Projects 113

Anaplastic Astrocytoma - Discontinued Products 114

Anaplastic Astrocytoma - Product Development Milestones 115

Featured News & Press Releases 115

Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 115

Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 115

Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 116

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Tables

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H2 2016 9

Number of Products under Development for Anaplastic Astrocytoma – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Anaplastic Astrocytoma – Pipeline by AngioChem Inc., H2 2016 17

Anaplastic Astrocytoma – Pipeline by Astellas Pharma Inc., H2 2016 18

Anaplastic Astrocytoma – Pipeline by Axelar AB, H2 2016 19

Anaplastic Astrocytoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 20

Anaplastic Astrocytoma – Pipeline by Burzynski Research Institute, Inc., H2 2016 21

Anaplastic Astrocytoma – Pipeline by Cavion LLC, H2 2016 22

Anaplastic Astrocytoma – Pipeline by Celldex Therapeutics, Inc., H2 2016 23

Anaplastic Astrocytoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 24

Anaplastic Astrocytoma – Pipeline by Novartis AG, H2 2016 25

Anaplastic Astrocytoma – Pipeline by Orbus Therapeutics, Inc., H2 2016 26

Anaplastic Astrocytoma – Pipeline by Pfizer Inc., H2 2016 27

Anaplastic Astrocytoma – Pipeline by Tocagen Inc., H2 2016 28

Anaplastic Astrocytoma – Pipeline by TVAX Biomedical, Inc., H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Stage and Target, H2 2016 33

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 39

Anaplastic Astrocytoma – Dormant Projects, H2 2016 113

Anaplastic Astrocytoma – Discontinued Products, H2 2016 114

List of Figures

List of Figures

Number of Products under Development for Anaplastic Astrocytoma, H2 2016 9

Number of Products under Development for Anaplastic Astrocytoma – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 14

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Top 10 Targets, H2 2016 32

Number of Products by Stage and Top 10 Targets, H2 2016 32

Number of Products by Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Routes of Administration, H2 2016 36

Number of Products by Stage and Routes of Administration, H2 2016 36

Number of Products by Molecule Types, H2 2016 38

Number of Products by Stage and Molecule Types, H2 2016 38

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports